I wonder how many 1 share OTC transactions ANY zero commission broker would allow. Maybe just one trade that day?? So you get one share that would be worth $6.00 today but no one holding shares will be able to trade them for 1-4 days while the RS is sorted out by brokers. 99% of the time the pps tanks when no one will buy at 6.00. It could lose 50% in a day.

So when they could sell maybe they get 3.00 for their 15 cent buy?!?!

LOL!!

so 2000 folks bought 1 share each today lol all thinking they will not be reversed out and have one share after reverse worth $8. are there really that many no commision brokers?

I guessed at 2000 2800 trades and 45000 shares traded

The only no commission one I use doesn't allow most otc and penny stocks but I haven't tried lately. Maybe it said it in a filing. I have seen this a lot in the last year as I check daily list daily but how many do not actually reverse you out

Y'know, on a leap year, we could add the day to any month we want.... I say we make a June 31...

haha.....yup, just like Feb. 29th adds a day to Feb 28th I added a day to January.

Nuthin' gets by you, LOL.

Edited with thanks.

January 32?

SIGY: effective Jan. 31,2024 a one for 40 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

I continue to like what these guys are doing. Got my avg down to .52 which all things considered where I started, is not bad, doing some trading along the way. I'd like to pickup another 30K at a dime or better to bring avg down to .44 which is in the range where a rally that develops could hit allowing the opportunity to reduce some risk. The restricted shares continue to be a majority of the outstanding which is a good sign and there has really never been much dumping

Picked up 15K at .11 bidding more, I really feel that at this price its a steal with market cap of 4 million bucks, and the CEO has a great track record, no game played, never late on filings, etc. This just needs more time. Share structure continues to be excellent with majority held by CEO and partner restricted

Market Cap Market Cap
4,247,283
05/15/2023
Authorized Shares
1,000,000,000
05/15/2023
Outstanding Shares
38,263,813
05/15/2023
Restricted
29,444,232
05/15/2023
Unrestricted
8,819,581
05/15/2023

seems a pump might be coming, unless it's already over.

no idea I just saw it when you mentioned it. Geez I could have at least lightened up a little, thats what GTC orders are for. Things have been so dead for so long here

what happened yesterday, more volume than the last year alone it seems

talk about dead money this has been, very discouraging. I know for sure that the company is doing what they should be doing, but the timeframes are just astronomical. Nothing to do but wait it out, but I feel the price is great down here if you want to build your position.

Sigyn Therapeutics - $SIGY Featured in PubCoInsight.

Sigyn Therapeutics is a San Diego-based medical technology firm that is looking to put an end to sepsis. For those who are unaware, sepsis is a life-threatening condition and one of the leading causes of death in hospitals around the world. Sigyn recently completed a clinical trial on animals with its EBP or Extracorporeal Blood Purification process. The company is now filing an investigational device exemption from the FDA as it now moves its clinical studies onto humans. If successful, it would open the doors to a massive global market with few competitors. Sigyn is seeking an uplisting to the NASDAQ exchange as well, and Goldman Small Cap Research has a 12-month price target of $9.00 for this OTC stock.

https://pubcoinsight.com/2022/06/21/crypto-stocks/

SIGY is a Gem Stock IMHO. If the company gets FDA approval, the device can cure the #1 cause of hospital deaths and the stock could soar up to $20 ??. As a matter of fact, the CEO took another company to NASDAQ before. He will take this company too.
Watch the interview of the CEO :

One of the best for sure!

Let us wait until another filtration company makes a big $plash with the FDA or perhaps big pharma or better yet both!

Great management here, maybe the best?

$SIGY CEO has taken a biomedical company to NASDAQ before and plans to do it again. It could potentially go to Nasdaq Exchange based on its track record.

https://www.cfodive.com/news/new-sigyn-cfo-maps-nasdaq-uplist-shelf-registration-strategy/621667/

Picked up another 6K at the .37 range and ready to buy more at .30, now a LIFETIME trading avg for RGNP/SIGO of .92, not bad at all. I continue to believe this is a great opportunity and am surprised there is not more activity at these prices, which may have to do with the fact that the float is so small due to the founders owning most of it, and they wont be selling a single share for sure. I'm telling you this is a great deal down here, as they progress towards a product the price will be driven up.

I'm ready to buy more down here in the 40 cent range, at $15 million market cap, the potential here is absolutely huge. company is very well run, i just dont have the visibility as to when it takes off but at these prices it's a steal. People will look back and scratch their heads.

Picked up another 5K shares a .425 the other day. Sorry but this stock is just plain cheap. The CEO seems to be organized while the market has no idea whats going on. I sort of wonder if this is the case for a number of stocks in the therapeutics realm. For now there isnt much we can do.

Treatment for Cytokine storm!

A better treatment for Sepsis, this has huge potential

Breakthrough product SIGY has

$SIGY Live on the Emerging Growth Conference in 30 minutes

Registration link here to interact with the Company live.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167383249

$SIGY CEO Presenting on the Emerging Growth Conference on January 5 Register Now

https://finance.yahoo.com/news/ceo-presenting-emerging-growth-conference-120000480.html

#SIGYN #Therapeutics #Cytokine #Sepsis #Covid19 #Vics #Ards #omicron

$SIGY Presenting Live on the Emerging Growth Conference 1/5/22

Register here to interact live with the Company:
https://investorshub.advfn.com/Emerging-Growth-Conference-39573/

well here we are at the end of a year with fantastic progress reported by the company and basically at an all time low since the reverse merger into Reign. Wow, all I can say is that this is literally a steal at these prices. I will attempt to pick up as many shares as possible at these prices. Tomorrow is a last opportunity to get peoples tax loss selling shares, we'll see if anything crosses the wire, it did today. Anything under a buck, or even 75 cents and certainly 50 cents is an absolute steal. Got my lifetime avg down to $1.08, and I have literally no complaints about that at all and am fully confident of their future. this is a life-changer (saver) for those that can benefit from the device being developed by Sigyn, and as investors we have an incredible opportunity to benefit.

I would also recommend to anyone to attend one of their webinars that they do regularly, it's been a while since I attended maybe 6 months ago but I recall that it was enlightening, and I would imagine that more recent ones would provide more up to date info.

$SIGY Likely Hike! Successful study proving treatment against sepsis! Possibly Covid-19 “Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis”??

https://finance.yahoo.com/news/sigyn-therapeutics-reports-successful-completion-123000152.html

$SIGY Breakthrough for Cytokine treatment! This stock will skyrocket

“Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines”??

https://finance.yahoo.com/news/sigyn-therapeutics-ceo-note-omicron-133000484.html

$SIGY Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines!

https://finance.yahoo.com/news/sigyn-therapeutics-ceo-note-omicron-133000484.html

$SIGY - Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines.

Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-related conditions that precipitate sepsis, today released a note authored by its Chairman and CEO, Jim Joyce.

https://finance.yahoo.com/news/sigyn-therapeutics-ceo-note-omicron-133000484.html

Mr. Joyce, CEO of $SIGY - @Sigyn_inc, discussed the benefits of blood purification technology, and addressed the concern of sepsis, specifically in COVID patients. Seems like this company is working hard to decrease the disease.

https://docwirenews.com/covid-19/jim-joyce-ceo-sigyn-therapeutics-on-blood-purification-technology-and-treating-sepsis-in-covid-patients/

$SIGY Doc Wire News interviewed CEO Jim Joyce "Jim Joyce, CEO, Sigyn Therapeutics, on Blood Purification Technology and Treating Sepsis in COVID Patients"

https://www.docwirenews.com/covid-19/jim-joyce-ceo-sigyn-therapeutics-on-blood-purification-technology-and-treating-sepsis-in-covid-patients/

You're welcome.

Thanks for sharing

SIGY - Sigyn Therapeutics Reported that it Successfully Completed a Study about Gram-Positive Bacterial Toxins Associated with Sepsis, a disease that kills many every year.

FULL PR: https://finance.yahoo.com/news/sigyn-therapeutics-reports-successful-completion-123000152.html

$SIGY - Sigyn INC Develops device to Help Prevent Covid-19

@Sigyn_inc, a leading Biotech company Develops device to Help Prevent Covid-19 and Sepsis Related Deaths. The company is in the final stages of clinical studies. Emerging Opportunity at $SIGY!

$SIGY developed a blood purification device!

$SIGY - @Sigyn_inc developed a blood purification device to treat Cytokine Storm (a leading cause of #Covid deaths) + sepsis (leading cause of hospital deaths).

Preparing for #FDA + #Nasdaq! Buy now before #Stock Price rises!

$SIGY $UNH $PG $PFE $NVO

SIGY really amazes me to be honest. I mean these guys go by the book, they are on time with their filings, they are organized with their press releases with a ton of detail, and they are making good progress with their business plan, and the CEO is very accessible, etc. etc. etc.. Why the stock languishes between 50 cents to a buck with random sometimes nonexistent volume I have no idea, granted a lot, no most of the stock is locked with the founders, there should be enough left in the float to trade. That said, when the heavy hitter news does hit, hopefully in the next year, this should take off with little resistance, BUT there is also risk that anyone that does have shares will want to get out and re-allocate their capital. We'll have to see, but for now I would take opportunities to buy at 40 - 60 cents and sell around a buck or more if there is a spike, which with stocks like this can happen at any time, so best be prepared with GTC orders.

well its dead here, as it often has been over the years. The more I follow the company, the more confident I am in the future even with a flagging share price, the future is bright. Problem has always been lack of volume. Any shares that you can be snarfed at like 60 cents are just absolute steals, under a buck is great as well. With such a low price that has been hit, I would sell lightly up thru 1.50 and beyond.

Bought at $1.16 today, could this go any lower, I dont know but I feel like its a steal down here, have at it folks.

well here we are in the pit at a buck and a quarter where the latest money raise was just done. I am continuing to buy down here, it could take a while, but this will take off in the appropriate time.

https://ih.advfn.com/stock-market/USOTC/reign-resources-pk-RGNP/stock-news/85118404/current-report-filing-8-k

May see a volume of 10k + today!

May see a few tutes loading today. They already own over 9% of shares. Good PR/news/catalysts.

$SIGY: InVitro-STUDY.... Sigyn-Therapy(TM) to adsorb viral pathogens including Covid-Sars



Sigyn Therapeutics(TM) Discloses In-Vitro Viral Pathogen Study
4:15 PM ET 4/21/21 | GlobeNewswire

Sigyn Therapeutics(TM) Discloses In-Vitro Viral Pathogen Study

Sigyn Therapy(TM) demonstrates the ability to address viral pathogens, including SARS-CoV-2 (COVID-19)

SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today disclosed initial in vitro study observations that demonstrated the ability of Sigyn Therapy(TM) to adsorb viral pathogens, including SARS-CoV-2 (COVID-19).

Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death. The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide. Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.

In the in vitro study, Sigyn reported the ability of the adsorbent components incorporated within Sigyn Therapy to address viral pathogens, including COVID-19. As the result of a two-hour exposure to Sigyn's adsorbent components, the presence of SARS-CoV-2 pseudotyped lentivirus was reduced by 68.8% from plasma. SARS-CoV-2 pseudotyped lentivirus is an established model previously utilized to study the development of antiviral drugs to treat COVID-19 and to assess the efficacy of vaccines against COVID-19 variants.

Sigyn Chairman and CEO, Jim Joyce stated: "While our first viral depletion observation may be compelling, we recognize this to be the first of several steps to validate viral depletion in combination with pro-inflammatory cytokine elimination as an effective strategy to mitigate virus-induced cytokine storms."

Sigyn Therapeutics further disclosed that it submitted a provisional patent application to the United States Patent and Trademark Office (USPTO) to protect this new discovery.

Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions. Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. The single-use medical device is designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide.

Since December 1, 2020, the Company has reported results from several in vitro studies designed to validate the capability of Sigyn Therapy to address a broad-spectrum of inflammatory targets.

Included among these studies was the simultaneous capture of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock. The dysregulated over-production of IL-1B, IL-6 and TNF-a can induce organ failure and cause death. An objective of this study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy. Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.

Sigyn Therapeutics has also reported the results of an in vitro pilot study that modeled the ability of Sigyn Therapy(TM) to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream. CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) participate in concert with freely circulating cytokines to further escalate Cytokine Storm Syndrome. CytoVesicles have previously been an elusive target as they can be 20-60 times larger than cytokines themselves. In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy's adsorbent components to deplete CytoVesicles from human blood plasma. After a two-hour interaction with Sigyn's adsorbent components, liposome concentrations in human blood plasma were reduced 90%. Previously published studies have validated liposomes as a model for the isolation of extracellular vesicles from blood based on the similarity of their size and structural characteristics.

The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.

About Sigyn Therapeutics

Sigyn Therapeutics(TM) is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy(TM) is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. ("Sigyn") that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "could," "will," "plan," "intend," "anticipate," "approximate," "expect," "potential," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn's future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn's expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn's business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn's business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity's ability to up-list to a national securities exchange, (viii) risks related to the combined entity's access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management's attention from Sigyn's ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn's views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn's views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jj@sigyntherapeutics.com

> Dow Jones Newswires

April 21, 2021 16:15 ET (20:15 GMT)

I'm interested in the Co. but I am not convinced that the price will not come down before or at least by the time they submit the info to the FDA. I have a bioteck right now that is in this fight and it is a very long process to get from processing FDA info, to submission to actual production of meds.

I am guessing that before the summer is out the price will drop well below the $2 area which will be a good entry point.

$SIGY Sigyn Therapeutics Announces Force Wealth Roundtable Forum with Goldman Small Cap Research
Press Release | 03/16/2021
The Event Occurs Tomorrow, March 17th at 12pm Eastern / 9am Pacific Time

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome, announced today that its Chairman and CEO, Jim Joyce, will participate in a “live” roundtable forum with Rob Goldman of Goldman Small Cap Research to discuss the science and clinical opportunities that underlie Sigyn Therapy™, a novel blood purification technology designed to treat sepsis and other life-threatening conditions that stem from cytokine storm syndrome.

This exclusive Force Family Office event occurs tomorrow, March 17, 2021 at 12:00pm Eastern Time / 9:00 am Pacific Time. Click on the following link to register for the event: https://forcewealth.com/portfolio-items/sigyn-03-17/?portfolioCats=28

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com

About Rob Goldman at Goldman Small Cap Research

Rob Goldman founded Goldman Small Cap Research in 2009. He leads the Firm's investment research strategy, and oversees a team of contractor analysts and editors, while serving as chief analyst. Rob has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund. As an investment manager, Rob's model portfolio was once ranked the 4th best small cap growth performer in the U.S. by Money Manager Review.

To learn more, visit www.goldmanresearch.com

About Force Family Office

FORCE works with Family Offices, Foundations, and Endowments by introducing them to leaders of public companies looking for open market buyers and privately held businesses at the capital acquisition stage. We’re constantly bringing unique opportunities and information to our community and make connections by actively seeking out best-in-class companies for introduction. In addition, our elite peer-to-peer community brings individuals, endowments and foundations together all over the world, facilitating both information sharing with symposiums, networking events, and conferences.

To learn more, visit www.forcewealth.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jj@sigyntherapeutics.com

$SIGY Sigyn Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Press Release | 03/08/2021
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced that Jim Joyce, its Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference that will take place virtually tomorrow March 9th and Wednesday March 10, 2021.

To register for the event, please visit: https://my.ct.events/register.aspx?meid=fc99b171-2574-4558-bda3-3ba391b6e555&rpid=75ab29bf-f328-45e8-9008-d5e88edeea28

Mr. Joyce’s presentation will be available beginning March 9, 2021 at 7:00am EST and can also be accessed at the investor relations section of the Sigyn Therapeutics website at www.sigyntherapeutics.com

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jj@sigyntherapeutics.com